From dimerix march announcement...
"
Following on from the disappointing result in our attempted IPO last year, Dimerix has conducted a full review of the strategic and budgetary effect of a lower cash holding. Importantly, Dimerix expects that achieving an interim readout of the clinical trial is achievable with the cash currently available.
Dimerix Management continue to explore non dilutive funding opportunities such as government grants, as well as monitoring appropriate timing to raise additional capital to accelerate the DMX-200 program and progress our pipeline development."
Doesn't even hint at looking for a back door entry......
SBN Price at posting:
1.1¢ Sentiment: Hold Disclosure: Held